- After a minimum follow-up of 5 years, more than 50% of patients with advanced melanoma who received a combination therapy of nivolumab (NIVO) and ipilimumab (IPI) were still alive.
Why this matters
- This 5-year analysis of CheckMate 067 represents the longest phase 3 follow-up for any checkpoint inhibitor combination therapy.
- Impressive improvements in PFS and OS were seen with NIVO+IPI in patients with advanced treatment-naïve melanoma. Duration of these benefits is unknown.
- 945 patients randomised to NIVO+IPI, NIVO, or IPI.
- Minimum follow-up now 60 months.
- Funding: Bristol-Myers Squibb.
- The median duration of response and median OS have not been reached under NIVO+IPI.
- 5-year PFS is 36%, 5-year OS is 52%.
- There were no large differences in the benefits between patients with or without BRAF mutations or between those with lower (
- “With this long follow-up, we can now say with a degree of certainty that PD-1 based therapy is an option for patients with advanced melanoma regardless of PD-L1 status and BRAF mutation,” said Teresa Amaral, Centre for Dermato-oncology, Eberhard Karls University Tübingen, Germany, who was not involved in the study.